Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adia MedADIA 14 3-1 Month Momentum % is -16.67% as of Aug. 01, 2026. GuruFocus rates ADIA with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 677 Healthcare Providers & Services companies, Adia Med ranks worse than 78.29% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-01), Adia Med's 3-1 Month Momentum % is -16.67%.
The industry rank for Adia Med's 3-1 Month Momentum % or its related term are showing as below:
ADIA's 3-1 Month Momentum % is ranked worse than 78.29% of 677
companies
in the Healthcare Providers & Services industry
Industry Median: -3.12
vs ADIA: -16.67
Adia Med (OTCPK:ADIA) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Adia Med 3-1 Month Momentum % Related Terms
ADIA vs GBCS, CCM, CDIX: 3-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, Adia Med's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adia Med 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Adia Med's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Adia Med's 3-1 Month Momentum % falls into.
Adia Med (OTCPK:ADIA) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adia Med (ADIA) has a 3-1 Month Momentum % of -16.67% as of Aug. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Adia Med and its competitors. According to the industry distribution chart, Adia Med ranks #530 out of 677 companies in the Healthcare Providers & Services industry, placing it in the top 78.3%.
Is Adia Med's 3-1 Month Momentum % too high?
Adia Med's current 3-1 Month Momentum % is -16.67%. Based on the distribution chart, Adia Med ranks #530 out of 677 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Adia Med has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Adia Med's 3-1 Month Momentum % compare to GBCS and CCM?
According to the Healthcare Providers & Services industry distribution chart, Adia Med ranks #530 out of 677 companies for 3-1 Month Momentum %. This places Adia Med in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Adia Med and its competitors. Adia Med's current 3-1 Month Momentum % is -16.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adia Med stock overvalued right now?
Adia Med (ADIA) has a current 3-1 Month Momentum % of -16.67%. The current 3-1 Month Momentum % is -16.67%. Adia Med's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Adia Med (ADIA), the current 3-1 Month Momentum % is -16.67% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adia Nutrition Inc focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Its products and the deployment of the therapies utilizing its products address various orthopedic issues, pain management, and wound repair. In addition, its products are able to be utilized in various other therapies to address anti-aging issues and other tissue repair desires. It operates in three segments The Biolete segment comprises the sale of supplements; Adia Med performs stem cell treatments to patients; and Adia Labs procures and sells stem cell products to outside clinics or to Adia Med. It derives revenue from Sales of supplements, Medical procedures, Sales of biologics and ancillary products.
14GF Score
Get the complete analysis for ADIA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADIA has been successfully added to your 
